
Elasticity and Thermal Stability are Key Determinants of Hearing Rescue by Mini-Protocadherin-15 Proteins
简介:
- 作者: Pedro De-la-Torre, Haosheng Wen, Joseph Brower, Karina Martínez-Pérez, Yoshie Narui, Frank Yeh, Evan Hale, Maryna V. Ivanchenko, David P. Corey, Marcos Sotomayor and Artur A. Indzhykulian
- 杂志: BioRxiv
- Doi: https://www.doi.org/10.1101/2024.06.16.599132
- 出版日期: 2024 Jun 17
论文中使用的产品/服务
Quotation shows PackGene:AAVs for this study were produced by PackGene, Houston, TX. Serotype AAV9-PHP.B vectors were packaged in HEK293T cells using polyethylenimine-mediated cotransfection of the pAAV transfer plasmid, pHelper plasmid, and RepCap plasmid pUCmini-iCAP-PHP.B.
Research Field:hearing and balance
AAV Serotype:AAV9-PHP.B
Targeted organ:ear
Animal or cell line strain:mice
摘要
Protocadherin-15 is a core protein component of inner-ear hair-cell tip links pulling on transduction channels essential for hearing and balance. Protocadherin-15 defects can result in non-syndromic deafness or Usher syndrome type 1F (USH1F) with hearing loss, balance deficits, and progressive blindness. Three rationally engineered shortened versions of protocadherin-15 (mini-PCDH15s) amenable for gene therapy have been used to rescue function in USH1F mouse models. Two can successfully or partially rescue hearing, while another one fails. Here we show that despite varying levels of hearing rescue, all three mini-PCDH15 versions can rescue hair-cell mechanotransduction. Negative-stain electron microscopy shows that all three versions form dimers like the wild-type protein, while crystal structures of some engineered fragments show that these can properly fold and bind calcium ions essential for function. In contrast, simulations predict distinct elasticities and nano differential scanning fluorimetry shows differences in melting temperature measurements. Our data suggest that elasticity and thermal stability are key determinants of sustained hearing rescue by mini-PCDH15s.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。
